Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 609 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Coronary Disease
Interventions
Ticagrelor 90 MG, Low-dose aspirin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
3
States / cities
Englewood, New Jersey • Flushing, New York • New York, New York
Conditions
Contrast-induced Nephropathy, Chronic Kidney Diseases
Interventions
Low-frequency therapeutic ultrasound (LOTUS), LOTUS System with Ultrasound Disabled
Device
Lead sponsor
Sonogenix
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Detroit, Michigan • Petoskey, Michigan • Pittsburgh, Pennsylvania + 1 more
Conditions
Chronic Kidney Disease, Cardiorenal Syndrome
Interventions
Doxycycline, Placebo (for Doxycycline)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Active, not recruiting Phase 1Phase 2 Interventional

Empagliflozin in ESKD - A Feasibility Study

NCT05687058
Conditions
Kidney Failure, Chronic, Heart Failure
Interventions
Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Jackson, Mississippi
Conditions
Heart Failure
Interventions
Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more
Conditions
Pulmonary Dysfunction, Median Sternotomy Recovery, Postoperative Pain
Interventions
Intercostal Nerve Cryoablation
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Heart Failure, Chronic Kidney Disease
Interventions
AZD9977, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 130 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Beverly Hills, California • Fountain Valley, California • Northridge, California + 22 more
Conditions
Chronic Kidney Disease
Interventions
Empagliflozin, Matching placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
47
States / cities
Huntsville, Alabama • Mesa, Arizona • San Diego, California + 38 more
Conditions
Ischemic Heart Disease
Interventions
Not listed
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Interventions
Tovinontrine (CRD-750), Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 19 more
Conditions
Cardiomyopathy, Chronic Kidney Disease, Anemia
Interventions
Darbepoetin alfa
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Neutropenia
Interventions
Mavorixafor, Placebo
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 20 more
Not listed No phase listed Observational Accepts healthy volunteers

Hypoxemia in Maintenance Hemodialysis Patients

NCT03045796
Conditions
Oxygen Saturation and the Relationship to Other Cardiac Variables, Maintenance Hemodialysis, Kidney Failure, Chronic
Interventions
Oxygen Saturation measured by WristOx
Device
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Urbana, Illinois
Conditions
Heart Failure, Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, Diabetes, Osteoporosis
Interventions
Multidisciplinary team interventions, Multidisciplinary team bimonthly visits either in person or via telephone., Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager
Other
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
65 Years and older
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Kansas City, Missouri • St Louis, Missouri
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

NCT00601302
Conditions
Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions
Amlodipine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Conditions
Heart Failure, Kidney Dysfunction
Interventions
Furosemide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Ranolazine, Ranolazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 78 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Cereset Research For Chronic Nausea

NCT05229107
Conditions
Nausea, Gastroparesis, Stress, Anxiety, Hyperarousal, Quality of Life, Vomiting, Heart Rate Variability
Interventions
Cereset Research
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
COVID-19, Long COVID
Interventions
MouthLabTM
Device
Lead sponsor
Edith Nourse Rogers Memorial Veterans Hospital
Federal
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bedford, Massachusetts
Conditions
Chronic Renal Impairment, Diabetes Mellitus
Interventions
Iopamidol injection 76%, iodixanol
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Kidney Disease, Chronic
Interventions
BI 690517, Placebo matching BI 690517, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
8,371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
53
States / cities
Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 46 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Completed Not applicable Interventional

Sapphire 3 CTO Study

NCT06358508
Conditions
Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery
Interventions
Sapphire 3 Coronary Dilatation Catheter
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Stanford, California • Torrance, California • Atlanta, Georgia + 5 more